Quarterly ResultMay 18, 2026, 01:46 PM
ReposiTrak Q3 Operating Income +24% to $2.3M; EPS $0.10
AI Summary
ReposiTrak reported third fiscal quarter 2026 financial results, with operating income increasing 24% to $2.3 million and diluted EPS at $0.10. Revenue remained flat at $5.9 million, attributed to a temporary shift in traceability onboarding activity following an FDA compliance deadline extension. The company also announced filing two new patents for its Touchless Traceability™ solution and a new collaboration with SPAR Group to enhance in-store operational execution. ReposiTrak continued its capital return program, redeeming preferred shares, repurchasing common shares, and declaring a quarterly dividend.
Key Highlights
- Q3 fiscal 2026 operating income increased 24% to $2.3 million.
- Q3 fiscal 2026 diluted EPS was $0.10.
- Q3 fiscal 2026 total revenue was $5.9 million, essentially flat year-over-year.
- Fiscal year-to-date revenue increased 5% to $17.7 million.
- Filed two patent applications for its Touchless Traceability™ solution.
- Redeemed 35,047 preferred shares for $375,000 in Q3.
- Repurchased 55,262 common shares for $550,000 in Q3.
- Declared a quarterly dividend of $0.02 per share.
Price Impact
More from TRAK